GSK 2586881

Drug Profile

GSK 2586881

Alternative Names: 2586881; APN-01; GSK2586881; Recombinant-human-soluble-angiotensin-converting-enzyme-2-Apeiron-Biologics; rhACE2; rhACE2-Apeiron-Biologics

Latest Information Update: 16 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apeiron Biologics
  • Developer Apeiron Biologics; GlaxoSmithKline
  • Class Antihypertensives; Antineoplastics; Recombinant proteins
  • Mechanism of Action ACE stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lung injury; Adult respiratory distress syndrome; Pulmonary arterial hypertension
  • Discontinued Cancer; Diabetic nephropathies; Heart failure; Hypertension; Myocardial infarction

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 May 2018 GlaxoSmithKline re initiates phase I trial in Adult respiratory distress syndrome (In volunteers) in Germany (IV) (NCT03000686)
  • 04 Dec 2017 GlaxoSmithKline terminates phase I trial in Adult respiratory distress syndrome (In volunteers) in Germany, following an interim analysis to conduct a thorough data review (IV) (NCT03000686)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top